Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) PT at $122.50

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been given an average rating of “Moderate Buy” by the nine analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $122.50.

LNTH has been the topic of several analyst reports. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities dropped their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Finally, Redburn Atlantic started coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock.

Institutional Investors Weigh In On Lantheus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC grew its stake in shares of Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after purchasing an additional 1,269,900 shares during the last quarter. Swedbank AB bought a new position in Lantheus in the 1st quarter valued at $26,346,000. Groupama Asset Managment bought a new position in Lantheus in the 3rd quarter valued at $439,000. Vanguard Group Inc. increased its stake in shares of Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after buying an additional 389,828 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of Lantheus during the second quarter worth $26,794,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $90.27 on Monday. The firm has a market cap of $6.28 billion, a P/E ratio of 14.90 and a beta of 0.51. The firm’s 50-day simple moving average is $102.48 and its 200-day simple moving average is $97.13. Lantheus has a twelve month low of $50.20 and a twelve month high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.